Hennion & Walsh Asset Management, Inc. Mirati Therapeutics, Inc. Transaction History

Hennion & Walsh Asset Management, Inc.

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Jan 10, 2024	BUY	$41.99 - $62.38 $54,377 - $80,782	1,295 Added 5.75%	23,831 $1.4 Million
Q3 2023 Oct 27, 2023	BUY	$27.8 - $45.35 $35,695 - $58,229	1,284 Added 6.04%	22,536 $981,000
Q2 2023 Aug 09, 2023	SELL	$36.13 - $49.49 $1,698 - $2,326	-47 Reduced 0.22%	21,252 $768,000
Q1 2023 Apr 20, 2023	BUY	$36.54 - $54.26 $56,125 - $83,343	1,536 Added 7.77%	21,299 $792,000
Q4 2022 Jan 12, 2023	BUY	$41.27 - $98.62 $430,693 - $1.03 Million	10,436 Added 111.89%	19,763 $895,000
Q3 2022 Nov 14, 2022	BUY	$59.5 - $86.7 $138,397 - $201,664	2,326 Added 33.22%	9,327 $651,000
Q2 2022 Jul 19, 2022	BUY	$39.16 - $88.71 $274,159 - $621,058	7,001 New	7,001 $470,000
Q4 2021 Feb 14, 2022	SELL	$132.01 - $190.29 $1.12 Million - $1.61 Million	-8,478 Closed	0 $0
Q3 2021 Nov 12, 2021	SELL	$132.13 - $177.45 $367,585 - $493,665	-2,782 Reduced 24.71%	8,478 $1.5 Million
Q2 2021 Aug 13, 2021	SELL	$144.0 - $179.73 $2.04 Million - $2.54 Million	-14,134 Reduced 55.66%	11,260 $1.82 Million
Q1 2021 May 17, 2021	BUY	$158.92 - $221.61 $4.04 Million - $5.63 Million	25,394 New	25,394 $4.35 Million

3.57M

36.6K

Ticker MRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,609,800
Description
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...

Get notified when there are updates to the investment portfolio of Hennion & Walsh Asset Management, Inc., based on Form 13F filings with the SEC.

Stay updated on Hennion & Walsh Asset Management, Inc. with notifications on news.